Gland Pharma EBITDA And Margins Improve Strongly
Operational performance also improved significantly during the quarter. EBITDA rose 48% year-on-year to ₹513 crore from ₹347.5 crore, while EBITDA margin expanded to 29% from 24%. Adjusted EBITDA margin improved further to nearly 30%.
According to the company, profitability was aided by favourable product mix, operating leverage, contract and pricing renegotiations, cost optimisation measures and improved efficiencies across existing products.
Gland Pharma CDMO Business Emerges As Key Growth Driver
The company’s CDMO business emerged as a major growth driver. The segment contributed 46% of total revenues in Q4FY26 and recorded 36% year-on-year growth during the quarter. For the full FY26 period, CDMO revenues also accounted for 46% of total sales and grew 28%.
Higher contribution from CDMO projects also supported revenue growth and margins during the quarter.
Gland Pharma New Product Launches Support Growth
Key product launches including Dalbavancin, Infuvite and multivitamins further boosted growth momentum. The company also highlighted strong traction from recently secured GPO contracts in the US market.
For FY26, Gland Pharma reported consolidated revenue growth of 14.5% along with an adjusted EBITDA margin of 26%. The base business delivered an adjusted EBITDA margin of 38%.
Gland Pharma Management Commentary And Outlook
Commenting on the results, Mr Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Our strong FY26 performance, reflected in consolidated revenue growth of 14.5% and an adjusted EBITDA margin of 26%, underscores the progress we are making across the businesses, including Cenexi. The 38% adjusted EBITDA margin of the base business has been supported by robust growth in the CDMO segment, alongside new product launches and improved profitability across our existing portfolio, driven by ongoing cost-efficiency initiatives. We remain confident in sustaining this momentum, supported by a pipeline of complex product launches and the continued ramp-up of CDMO partnerships.”
Gland Pharma ₹20 Final Dividend Announced
The board recommended a final dividend of ₹20 per equity share for FY26, subject to shareholder approval at the upcoming Annual General Meeting.
The record date for the dividend has been fixed as August 11, 2026, and payment is expected within 30 days of approval.
Gland Pharma Valuation And Technical Picture
On the valuation front, Gland Pharma currently trades at a price-to-earnings ratio of 36.33 and a price-to-book ratio of 3.36. The company’s market capitalisation stands at ₹30,781 crore.
From a technical perspective, the stock remains firmly bullish. Its 14-day Relative Strength Index stood at 57.3, indicating neutral-to-positive momentum, while the stock continues to trade above all 8 key simple moving averages.
Gland Pharma shares have rallied 17% over the past month, gained 22% on a year-to-date basis, risen 43% over the last year and surged 57% over the past three years.
Source: BSE, Dalal Street Investment Journal (DSIJ)
